Pathophysiology, diagnosis and treatment of endometriosis

Minerva Ginecologica

Volumn 56, Issue 5, 2004, Pages 419-435

  Schindler, A E ^a,b  

^a Institute for Medical Research and Education Essen   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Endometriosis, diagnosis; Endometriosis, physiopathology; Endometriosis, therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BUSERELIN; CETRORELIX; CYPROTERONE ACETATE; DANAZOL; DIENOGEST; DYDROGESTERONE; ESTRADIOL; EXEMESTANE; FORMESTANE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MIFEPRISTONE; NAFARELIN; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIPTORELIN; UNINDEXED DRUG;

ACNE; CLINICAL EXAMINATION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; EDEMA; ENDOMETRIOSIS; GENETIC RISK; HIRSUTISM; HOT FLUSH; HUMAN; IMMUNOPATHOGENESIS; LAPAROSCOPIC SURGERY; LAPAROSCOPY; LARYNX DISORDER; METABOLIC DISORDER; MUSCLE CRAMP; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREVALENCE; RECURRENCE RISK; REVIEW; SEBORRHEA; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYSTEMATIC REVIEW; TREATMENT PLANNING; VAGINA DISEASE; WEIGHT GAIN;

ENDOMETRIOSIS; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 11144351005     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Rokitansky C von. Über Uterusdrüsenneubildung im Uterus. Z k k Ges Aerzte Wien 1860;37:577.
2. Recklinghausen F von. Die Adenomyome und Cystadenome der Uterus- und Tubenwandung; ihre Abkunft von Resten des Wolff'schen Ganges. Berlin: Hirschwald; 1896.
3. Cullen TS. Adenomyoma of the round ligament. J Hopkin's Hosp Bull 1896;7:122-14.
4. Pfannenstiel J. Über die Ademnome des Genitalstranges. Verhandl Dtsch Ges Gynäkol 1897;7:195.
5. Russel WW. Aberrant portions of the Muellerian duct found in the ovary. Bull J Hopkin's Hosp 1899;16:8-10.
6. Meyer R. Über eine adenomatöse Wucherung der Serosa in eine Bauchnarbe. Monatsschrift Geburtsh Gynäk 1903;49:32-41.
7. Meyer R. Über entzündliche heterotope Epithelwucherungen im weiblichen Genitalgebiet und über das bis in die Wurzel des Mesocolon ausgedehnte benigne Wucherungen des Darmepithels. Virchow's Arch Path Anat Physiol 1909;195:487.
8. Ivanoff NF. Drüsiges zystenhaltiges Uterusfibrom, kompliziert durch Sarkom und Karzinom Monatsschrift Geburtsh Gynäk 1897;37:327-39.
9. Meyer R. Über den Stand der Frage der Adenomyosttis und Adenomyome im allgemeinen und im besonderen über Adenomyositisseroepithelialis und adenomyometritis sacomatosa. Zentralbl Gynäkol 1919;43:745-50.
10. Nowak E. The significance of uterine mucosa in the fallopian tube, with discussion of the origin of aberrant endometrium. Am J Obstet Gynecol 1926;12:484-525.
11. Sampson JA. Perforating haemorrahgic (chocolate) cyst of the ovary. Their importance and especially relationship to pelvic adenomas of endometrial type. Arch Surg 1921;3:245-323.
12. Ebert AD. Endometriose. Berlin: Walther de Gruyter; 2003.
13. Koninckx PR, Kennedy SH, Barlow DH. Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 1998;4:741-51.
14. Leyendecker G, Herbertz M, Kunz G, Mall G. Endometriosis results from the dislocation of basal endometrium. Hum Reprod 2002;17:2725-36.
15. Kühn W, Pickartz H. Klinische Pathologie des weiblichen Genitaltraktes. Stuttgart: Wissenschaftl. Verlagsgesellschaft; 2001.
16. Vasquez G, Cornillie F, Brosens IA. Peritoneal endometriosis: scanning electronmicroscopy and histology of minimal pelvic lesions. Fertil Steril 1984;42:696-703.
17. Schweppe KW. Aktivität der Endometriose - Therapierelevanz bei Schmerz- und Sterilitätspatientinnen. In: Mettler L, editor. Endometriose 2000. Frankfurt: PMI; 2000.p.58-67.
18. Schweppe KW. Klinik und Morphologie der Endometriose. Stuttgart. New York: Schattauer; 1984.
19. Somigliana E, Infantino M, Candiani M, Vignali M, Chiodini A, Busacca M et al. Association rate betweeen deep peritoneal endometriosis and other forms of the disease: pathogenetic implications. Hum Reprod 2004;19:168-71.
20. Kennedy S. Genetics of endometriosis. In: Tulandi T, Redwine D, editors. Endometriosis: Advances and controversies. New York/Basel: Marcel Dekker; 2003.p. 55-66.
21. Dmowski WP, Steele RW, Becker GF. Deficient cellular immunity in endometriosis. Am J Obstet Gynecol 1981;141:377-83.
22. Schindler AE, Regidor PA. Endometriose. In: Dudenhausen JW, Schneider HPG, Bastert G, editors. Frauenheilkunde und Geburtshilfe. Berlin/New York; Walther de Gruyter; 2003.p.417-25.
23. Arruda MS, Pella CA, Abao MS, Benetti-Pinto CC. Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of brazilian women. Hum Reprod 2003;18:756-9.
24. Husby GK, Hansen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 2003;82:649-53.
25. Mettler L, Schollmeyer T, Lehmann-Willenbrock E, Schuppler U, Schmutzler A, Shukla D et al. Accuracy of laparoscopic diagnosis of endometriosis. JSLS 2003;7:15-8.
26. Hoyme UB. Rationelle Diagnostik genitaler Infektionen-Teil 2. Geburtsh Frauenh 2002;62:R201-20.
27. Laufer MR, Sanfilippo J, Rose G. Adolescent endometriosis: diagnosis and treatment approaches. J Pediatr Adolesc Gynecol 2003;16 Suppl 3:53-11.
28. Harada T, Kubota T, Aso T. Usefulness of CA 19-9 versus CA-125 for the diagnosis of endometriosis. Fertil Steril 2002;78:733-9.
29. Falcone T, Badalwy MA. Serum and peritoneal markers for endometriosis. In: Tulandi T, Redwine D, editors. Endometriosis. Advances and controversies. New York/Basel: Marcel Dekker; 2003.p. 123-50.
30. Cheng YM, Wong ST, Chon CY. Serum CA-125 in pre-operative patients of high risk for endometriosis. Obstet Gynecol 2002;99:375-80.
31. American Society of Reproductive Medicine. Revised American Society of Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997;67:817-21.
32. Zanardi R, DelFrate C, Zuiani C, Pazzochi M. Staging of pelvic endometriosis based on MRI findings versus laparoscopic. Classification according to the American Fertility Society. Abdom Imaging 2003;28:733-42.
33. Vercellini P, Chapron C, De Giorgi O, Consonni D, Frontino G, Crosignani PG. Coagulation or excision of ovarian endometriosis? Am J Obstet Gynecol 2003;188:606-10.
34. Ho HY, Lee RK, Hwo YM, Lim MH, Su JT, Tsai YC. Poor response of ovaries with endometrioma previously treated with cystectomy to controlled ovarian hyperstimulation. J Assist Reprod Genet 2002;19:507-11.
35. Duepru HJ, Senapore AJ, Delancy CP, Marcello PW, Brady KM, Falcone T. Laparoscopic resection of deep pelvic endometriosis with rectovaginal involvement. J Am Coll Surg 2002;195:754-8.
36. Nezhat CH, Malik S, Osias J, Nezhat F, Nezhat C. Laparoscopic management of 15 patients with infiltrating endometriosis of the bladder and a case of intravesical endometrial adenosarcoma. Fertil Steril 2002;78:872-5.
37. Soysal ME, Soysal S, Gurses E, Ozer S. Laparoscopic presacral neurolysis for endometriosis related pelvic pain. Hum Reprod 2003;18:588-92.
38. Jacobson TZ, Barlow DH, Konickx PR, Ovile D, Farquqr C. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev 2002;(4): CD001398.
39. Donnez J, Squifflit J, Pirard C, Jadoul P, Wyns C, Smets M. The efficacy of medical and surgical treatment of endometriosis associated pain. Gynecol Obstet Invest 2002;54 Suppl 1:2-7.
40. Schindler AE, Foertig P, Kienle E, Regidor PA. Early treatment of endometriosis with GnRH-agonists: impact on time to recurrence. Eur J Obstet Gynaecol Reprod Biol 2000;93:123-5.
41. Kistner RW. The use of progestins in the treatment of endometriosis. Am J Obstet Gynecol 1958;75:204-78.
42. Noble AD, Letchworth AT. Medical treatment of endometriosis: a comparative trial. Postgrad Med J 1979;55 Suppl 5:37-9.
43. Adamson D. Endometriosis: traditional perspectives, current evidence and future possibilities. Int J Fertil 2001;46:151-68.
44. Surrey ES. Medical therapy for endometriosis. An overview. In: Tulandi T, Redwine D, editors. Endometriosis. Advances and controversies. New York/Basel: Marcel Decker; 2003.p. 107-88.
45. Schindler AE. Medikamentöse Therapie der Frauen mit Endometriose und Schmerzen. Frauenarzt 2004;45:546-51.
46. Körte W, Beck KJ, Scherholz KP. Operative Behandlung der Endometriose und Langzeittherapie mit Lynestrenol. Geburtsh Frauenheilk 1970;30:122-32.
47. Hugentobler R. Die Behandlung der Endometriose mit hochdosiertem Primolut-Nor. Thesis Zürich 1971.
48. Schindler AE. Prognose der Endometriose nach Therapie. Endometriose 1984;3:8-10.
49. Mettler L. Dreistufentherapie der Endometriose. In: Witschki M, editor. Genitalendometriose. Ätiologie, Pathologie, Klinik und Therapie. Basel: Karger; 1985. p.66-75.
50. Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987;1:13-23.
51. Haney AF, Weinberg JB. Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with Medroxyprogesterone acetate. Am J Obstet Gynecol 1988;159:450-4.
52. Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988;72:323-7.
53. Schlaff WD, Dugoff L, Damewood MD, Rock JA. Megestrol acetate for treatment of endometriosis. Obstet Gynecol 1990;75:646-8.
54. Overton CE, Lindsay PC, Johal B, Coillins SA, Siddle NC, Shaw RW et al. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril 1994;62:701-7.
55. Harrison RF, Barry-Kinsella C. Efficacy of medroxy-progesterone treatment in fertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000;74:24-30.
56. Vercellini P, de Giorgi O, Oldami S, Cortesi I, Panazza S, Crosignani PG. Depotmedroxyprogesterone acetate versus an oral contraceptive combined with very low dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996;175:396-401.
57. Vercellini P, Aimi G, Panazza S, de Giorgi O, Pessole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999;72:505-8.
58. Moore C, Köhler G, Müller A. The treatment of endometriosis with dienogest. Drugs Today 1999:35 Suppl G41-52.
59. Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P et al. Prospective randomized study comparing the GnRH-agonist leuproreline acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 2001;15:2002-9.
60. Vercellini P, de Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for the symptomatic endometriosis. Fertil Steril 2002;77:52-61.
61. Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis (Cochrane review). In: Cochrane library, Issue 2. 2004. Chichester, UK: John Wiley & Sons, Ltd.
62. Schweppe KW. Progestogens and endometriosis. Gynaecol Forum 2004;9:26-9.
63. Köhler H. [Hormone therapy of endometriosis-principles and clinical aspects of gestagen treatment] Zentralbl Gynakol 1995;117 Suppl:6-13.
64. Vercellini P, Frontino G, De Girogi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel- releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80:305-9.
65. Dmowski WP, Cohen MR, Wilhelm JL. Endometriosis and ovulatory failure: does it occur? Should ovulatory stimulating agents be used? In: Greenblatt RB editor. Recent advances endometriosis. Amsterdam: Exerpta Medica; 1975.p.129-36.
66. Lauerson NH, Wilson KH, Birnbaum S. Danazol: an antigonadotropic agent in the treatment of pelvic endometriosis. Am J Obstet Gynecol 1975;123:742-7.
67. Young MD, Blackmore WJ. The use of danazol in the management of endometriosis. J Int Med Res 1977;5 Suppl 3:86-91.
68. Greenblatt RB, Tzingouonis V. Danazol treatment of endometriosis: long-term follow-up. Fertil Steril 1979;32:518-20.
69. Ward D. Dosage aspects of danazol therapy in the treatment of endometriosis. Postgrad Mat J 1979;55 Suppl 5:7-9.
70. Biberoglu KO, Behrmann SJ. Dose aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 1981;139;645-54.
71. Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis. Analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37:737-46.
72. Selak V, Farquar L, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis (Cochrane Review). In: The Cochrane Library Issue 4, 2003. Chichester, UK; John Wiley and Sons, Ltd.
73. Igarachi M, Tizuka M, Abe Y, Ibuki Y. Normal vaginal danazol therapy for pelvic endometriosis in particular deeply infiltrating endometriosis. Hum Reprod 1998;13:1952-6.
74. Buttram VC, Belue B, Reiter R. Interim report. A study of danazol for treatment of endometriosis. Fertil Steril 1982;37:478-83.
75. Schweppe KW. Therapieerfolge und Rezidivrate nach Endometriosebehandlung. Endometriose 1987;5:4-11.
76. Pierce SJ, Gazvani MR, Farquharson RG. Long-term use of gonadotropin-releasing hormone analogues and hormone replacement therapy in the management of endometriosis: a randomized trial with a six year follow-up. Fertil Steril 2000;74:964-8.
77. Schindler AE, Bühler K, Mettler L, Fuchs U, Cirkel U, Ochs H et al. Treatment of endometriosis with the GnRH-agonist Buserelin (Suprecur®): a multicentre study. Geburtsh Frauenh 1994;54:569-73.
78. Regidor PA. Regidor M, Heck M, Bier U, Schindler AE. Behandlung der Endometriose mit dem GnRH-analogon Nafarelin. Wirksamkeit und Verträglichkeit von Synarella. Gynäkol Praxis 1995;19:669-72.
79. Schindler AE, Bühler K, Gerhard I, Wiedemann R, Kimmig R, Schüssler B et al. Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study. Zentralbl Gynäkol 1994;116:679-86.
80. Regidor PA, Schindler AE, Bühler K, Gerhard I, Kimmig R, Meinen K et al. Ergebnisse eines Langzeit Follow-up bei der Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat-Depot (Enantone®-Gyn Monats-Depot). Zentralblatt Gynäkol 1996;118:283-90.
81. Regidor PA, Regidor M, Kato K, Bier UW, Buhler K, Schindler AE. Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelin acetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 1997;73:153-60.
82. Schindler AE. Kombiniertes chirurgisch-hormonelles Management der Endometriose. Langzeit Follow-up. Zentralbl Gynäkol 1999;121:325-9.
83. Barbieri RL. Gonadotropin releasing hormone agonist and antagonist for endometriosis. In: Tulandi T, Redwine D editors. Endometriosis. Advances and controversies. New York/Basel: Marcel Dekker; 2003. p.210-43.
84. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprorelin acetate depot and hormonal add- back in endometriosis; a 12 month-study. Obstet Gynecol 1998;91:16-24.
85. Olive DL. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004;3:83-9.
86. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotropin-releasing analogues for endometriosis: bone mineral density (Cochrane review). In: The Cochrane library, Issue 1, 2004. Chichester, UK; John Wiley and Sons, Ltd.
87. Surrey ES, Silverberg KM, Surrey MD, Schoolcraft WB. Effect of a prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilisation and embryo transfer in patients with endometriosis. Fertil Steril 2002;78:699-704.
88. Rickes D, Nickel I, Kropf S, Kleinstein J. Increased pregnancy rates after ultalong postoperative therapy with gonadotropin-releasing hormone analogues in patients with endometriosis. Fertil Steril 2002;78:757-62.
89. Kuhlmann M, Gärtner A, Schindler EM, Regidor PA, Bühler K, Schindler AE. Uterine Leiomyomata and sterility. Therapy with gonadotropin-releasing hormone agonist and leiomyomectomy. Gynecol Endocrinol 1997;11:169-74.
90. Henzel MR, Corson SL, Moghissi K, Butram VC, Berqvist C, Jacobson J for the Nafarelin Study Group. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter, double-blind, comparative clinical trial. N Engl J Med 1988;318:485-9.
91. Dmowski WP, Radwanska E, Binor Z, Tammon I, Pepping P. Ovarian suppression induced with buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril 1989;51:395-400.
92. Kennedy S, Williams I, Bridribb J, Barlow D, Shaw R. A comparison of nafarelin acetate and danzol in the treatment of endometriosis. Fertil Steril 1990;53:998-1003.
93. Shaw R. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Study Team. Fertil Steril 1992;58:265-72.
94. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET). Fertil Steril 1992;57:514-22.
95. Wheeler J, Knittle J, Miller J. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol 1992;167:1367-71.
96. Rock J, Truglia J, Caplan R. Zoladex endometriosis study grouop. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstet Gynecol 1993;82:198-205.
97. Wright S, Valdes C, Dunn R, Franklin R. Short-term Lupron or danazol therapy for pelvic endometriosis. Fertil Steril 1995;63:504-7.
98. Goserelin depot versus danazol in the treatment of endometriosis. Australian/New Zealand experience. Aust N Z J Obstet Gynecol 1996;36:55-60.
99. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PM. A gonadotropin releasing hormone agonist versus a low dose contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;30:75-9.
100. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group. Fertil Steril 1996;66:911-9.
101. Küpker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12-16.
102. Kettel LM, Murphy AA, Murales AJ, Ulman A, Beaulieu EE, Yen SSC. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8.
103. Kettel LM, Murphy AA, Murales AJ, Yen SSC. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am Gynecol 1998;178:1151-6.
104. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynaecological therapy. Steroids 2003;68:1019-32.
105. Bulun S, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann NY Acad Sci 2002;955:75-85, discussion 86-8, 396-406.
106. Bulun SE, Zeituon K, Talyama K, Noble L, Michael D, Simpson I et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999;6:293-301.
107. Razzi S, Fava A, Sartini A, De Simone S, Cobellis L, Petraglia F. Treatment of severe recurrent endometriosis with aromatase inhibitors in a young ovarectomized women. BJOG 2004;111:182-4.
108. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effect of postsurgical administration of gazerelin plus anastrazole compared to gazerelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-7.
109. Ishihara H, Kitawaki J, Kado N, Koshiba H, Fushiki S, Honjo H. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome expression ineutopic endometrium from women with endometriosis, adenemyosis or leiomyomas. Fertil Steril 2003;79 Suppl 1:735-42.
110. Shippen ER, West WJ. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81:1395-8.
111. Müller MD, Dreher E, Taylor RM. Endometriosis and angiogenesis. On the tail of a riddle. Geburtsh Frauenheilk 2000;60:585-93.
112. Nap AW, Griffioen W, Dunselman GAJ, Bouma-Ter Steege JCA, Thijssen VLJL, Evers LH et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89:1089-95.
113. Nothnick WW, Hooghe TMD. Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimens. Gynecol Obstet Invest 2003;55:189-98.
114. Schindler AE. Unterbauchschmerzen: Klinik, Diagnostik und Differentialdiagnostik. Frauenarzt 2004;45:130-5.